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Epstein-Barr virus (EBV) growth transformation of pri-
mary B lymphocytes into indefinitely proliferating lym-
phoblastoid cell lines (LCLs) depends on the concerted
activities of a subset of viral proteins expressed during
latency. EBV drives quiescent B cells into S phase and con-
sequently a host response is activated that includes expres-
sion of p53 and its target genes. Since LCLs retain wild-
type p53, it was of interest to determine what contribution
the p53 pathway may have in controlling established LCL
growth and EBV-mediated transformation of primary B
cells.
We found that liberation of p53 through chemical antag-
onism of one of its major ubiquitin ligases, MDM2, led to
apoptosis of established LCLs and suppressed EBV-medi-
ated transformation of primary B cells. The activation of
latent p53 induced target genes associated with apoptosis
and was antagonized by constitutive NFκB activity in
LCLs. Furthermore, the NFκB-dependent antagonism of
p53 was not at the p53-dependent transcriptional level,
but rather involved increasing the level of steady-state
MDM2 protein. The consequence of these effects through
NFκB is to increase the MDM2/p53 ratio, thereby sensitiz-
ing cells to MDM2 antagonism. This mechanism, likely
through increased MDM2 translation, may provide a
novel means by which NFκB activating oncogenes sup-
press wild-type p53 activity and overcome the oncogenic
stress checkpoint. Furthermore, the acquisition of Nutlin-
sensitivity in EBV-infected cells provides a novel system
for studying the pathways that dictate LCL survival and
regulate EBV transformation. Finally, MDM2 antagonists
may be considered alone or in combination with NFκB
inhibition for therapeutic intervention in EBV-associated
malignancies expressing wild-type p53.
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